Stockreport

Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic disease Carmel Nanthakumar, PhD, joins as VP, Translational Biology, following [Read more]